Decade-long use of continuous combined hormone replacement therapy is associated with better health-related quality of life in postmenopausal women, as measured by the generic 15D instrument

Journal of the British Menopause Society

Volumn 11, Issue 4, 2005, Pages 145-150

  Ylikangas, Stiina ^a   Sintonen, Harri ^b   Heikkinen, Jorma ^c  

^a ORION CORPORATION   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c OULU DEACONESS INSTITUTE   (Finland)

Author keywords

15D instrument; Estradiol valerate; Health related quality of life; Low dose continuous combined hormone replacement therapy; Medroxyprogesterone acetate

Indexed keywords

ESTRADIOL VALERATE PLUS MEDROXYPROGESTERONE ACETATE; INDIVINA;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DISEASE CONTROL; DRUG DOSE REDUCTION; DRUG USE; FEMALE; FINLAND; FOLLOW UP; HORMONE SUBSTITUTION; HUMAN; INSTRUMENTATION; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SYMPTOMATOLOGY; TREATMENT DURATION;

ADULT; AGED; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FEMALE; FINLAND; FOLLOW-UP STUDIES; HEALTH STATUS; HUMANS; MEDROXYPROGESTERONE 17-ACETATE; MIDDLE AGED; POSTMENOPAUSE; PSYCHOMETRICS; QUALITY OF LIFE; QUESTIONNAIRES;

EID: 30944467098     PISSN: 13621807     EISSN: 13621807     Source Type: Journal    
DOI: 10.1258/136218005775544291     Document Type: Article

References (23)

1. Maclennan AH, Broadbent JL, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev 2004;(4): CD002978
2. North American Menopause Society. Recommendations for estrogen and progestogen use in peri-and postmenopausal women: October 2004 position statement of the North American Menopause Society. Menopause 2004;11:589-600
3. Executive Committee of the International Menopause Society. Position statement: Guidelines for the hormonal treatment of women in the menopause transition and beyond. Available at www.imsociety.org/PDF/ news_IMS§atement_15.10.04.pdf (last accessed 2 June 2005)
4. Skouby SO, Barlow D, Samsioe G, et al. European Menopause and Andropause Society (EMAS). Climacteric medicine: European Menopause and Andropause Society (EMAS) statements on postmenopausal hormonal therapy. Maturitas 2004;48:19-25
5. Minelli C, Abrams KR, Sutton AJ, Cooper NJ. Benefits and harms associated with hormone replacement therapy: clinical decision analysis. BMJ 2004;328:371-7
6. Col NF, Weber G, Stiggelbout A, Chuo J, D'Agostino R, Corso P. Short-term menopausal hormone therapy for symptom relief: an updated decision model. Arch Intern Med 2004;164:1634-40
7. Heikkinen JE, Vaheri RT, Ahomaki SM, Kainulainen PMT, Viitanen AT, Timonen UM. Optimizing continuous-combined hormone replacement therapy for postmenopausal women: a comparison of six different regimens. Am J Obstet Gynecol 2000;182:560-7
8. Heikkinen J, Vaheri R, Kainulainen P, Timonen U. Long-term continuous-combined hormone replacement therapy in the prevention of postmenopausal bone loss: a comparison of high-and low-dose estrogen-progestin regimens. Osteoporosis Int 2000;11:929-37
9. Heikkinen J, Vaheri R, Timonen U. Long-term safety and tolerability of continuous-combined hormone therapy in postmenopausal women: results from a seven-year randomised comparison of low and standard doses. J Br Menopause Soc 2004;10:95-102
10. Sintonen H, Johansson S, Ohinmaa A, Apajasalo M, Kainulainen P, Heikkinen J. Measuring health-related quality of life in women on hormone replacement therapy. Expert Rev Pharmacoeconomics Outcomes Res 2003;3:351-61
11. Sintonen H. The 15D instrument of health-related quality of life: properties and applications. Ann Med 2001;33:328-36
12. Sintonen H. The 15D Measure of Health-Related Quality of Life: Reliability, Validity and Sensitivity of Its Health State Descriptive System. Working Paper 41. Melbourne: National Centre for Health Program Evaluation, 1994. Available at www.buseco.monash.edu.au/centres/che/ publication.php#4 (last accessed 21 June 2005)
13. Sintonen H. The 15D Measure of Health-Related Quality of Life. II. Feasibility, Reliability and Validity of Its Valuation System. Working Paper 42. Melbourne: National Centre for Health Program Evaluation, 1995. Available at www.buseco.monash.edu.au/centres/che/ publication.php#4 (last accessed 21 June 2005)
14. Stavem K. Reliability, validity and responsiveness of two multi-attribute utility measures in patients with chronic obstructive pulmonary disease. Qual Life Res 1999;8:45-54
15. Hawthorne G, Richardson J, Day NA. A comparison of the Assessment of Quality of Life (AQoL) with four other generic utility instruments. Ann Med 2001;33:358-70
16. Bruhat M, Rudolf K, Vaheri R, Kainulainen P, Timonen U, Viitanen A. Effective bleeding control and symptom relief by lower dose regimens of continuous combined hormone replacement therapy. A randomized comparative dose-ranging study. Maturitas 2001;40:259-71
17. Mattsson L-Å, Skouby SO, Heikkinen J, Vaheri R, Mäenpää J, Timonen U. A low-dose start in hormone replacement therapy provides a beneficial bleeding profile and few side-effects: randomized comparison with a conventional-dose regimen. Climacteric 2004;7:59-69
18. Karlberg J, Mattsson L-Å, Wiklund I. A quality of life perspective on who benefits from estradiol replacement therapy. Acta Obstet Gynecol Scand 1995;74:367-72
19. Gambacciani M, Ciaponi M, Cappagli B, et al. Effects of low-dose, continuous combined estradiol and noretisterone acetate on menopausal quality of life in early postmenopausal women. Maturitas 2003;44:157-63
20. Thunell L, Stadberg E, Milsom I, Mattsson L-Å. A longitudinal population study of climacteric symptoms and their treatment in a random sample of Swedish women. Climacteric 2004;7:357-65
21. Thunell L, Stadberg E, Milsom I, Mattsson L-Å. Changes in attitudes, knowledge and hormone replacement therapy use: a comparative study in two random samples with 6-year interval. Acta Obstet Gynecol Scand 2005;84:395-401
22. Stenberg Å, Heimer G, Holmberg L, Ulmsten U. Prevalence of postmenopausal symptoms in two age groups of elderly women in relation to oestrogen replacement therapy. Maturitas 1999;33:229-37
23. Wiklund I, Holst J, Karlberg J, et al. A new methodological approach to the evaluation of quality of life in postmenopausal women. Maturitas 1992;14:211-24